Close Menu

NEW YORK – Bioprinting technology developer Cellink has signed an agreement to acquire all shares of German precision dispensing firm Scienion for €80 million ($94.8 million).

Under the terms of the deal, Boston-based Cellink will acquire Scienion for €40 million in cash and €40 million in shares through 2,814,032 newly issued shares at a price of SEK 146.6 per share. The transaction will give Scienion's shareholders about a 5 percent voting stake and roughly 7 percent of the firm's share capital. Following the acquisition, Scienion will retain its current management. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.